Nurse Practitioner in Standish, MI Accepting Medicare

6 Nurse Practitioner nurses found. Showing 1 - 6

Kristin A Lance, CFNP, RN, MSN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 805 W Cedar St, Standish, MI 48658 Phone: 989-846-3545    Fax: 989-846-3557

Mrs. Melinda Lee Hawley, FNP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 4489 M-61, Standish, MI 48658 Phone: 989-846-2600    Fax: 989-846-2601

Andrew Allan Slocum, MSN, FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 805 W Cedar St, Standish, MI 48658 Phone: 989-846-4888

Bree-ann Christine Dowd, Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 805 W Cedar St, Standish, MI 48658 Phone: 989-846-4888    Fax: 989-846-3538

Mr. Aaron Joseph Korczowski, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1064 W Cedar St, Standish, MI 48658 Phone: 989-654-2491

Susan Elizabeth Jock, NP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 805 W Cedar St, Standish, MI 48658 Phone: 989-846-4535    Fax: 989-846-6580

News Archive

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

Kinder chemistry promises cleaner and safer pharmaceuticals with fewer side-effects

A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

Read more Medical News

› Verified 9 days ago